Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors

Table 4

Delphi list of included studies.

Final Delphi List	CheckMate 066 Robert et al. 2015	CheckMate 067 Wolchok Et al. 2017	CheckMate 037 Larkin et al. 2017	CheckMate 069 Hodi et al. 2016	KEYNOTE-006 Schachter Et al. 2017	KEYNOTE-002 Ribas et al. 2015
Treatment allocation.; (a) Was a method Of randomization performed?; (b) Was the treatment allocation concealed?	Yes; Yes	Yes; Yes	Yes; Yes	Yes; Yes	Yes; Yes	Yes; Yes
Were the groups similar at baseline regarding the most Important Prognostic indicators?	Yes	Yes	Yes	Yes	Yes	Yes
Were the eligibility criteria specified?	Yes	Yes	Yes	Yes	Yes	Yes
Was the outcome assessor blinded?	Yes	Yes	Yes	Yes	Yes	Yes
Was the care provider blinded?	Yes	Yes	Yes	Yes	No	Yes
Was the patient blinded?	Yes	Yes	Yes	Yes	No	Yes
Were point estimates and Measures Of Variability Presented for the Primary outcome measures?	Yes	Yes	Yes	Yes	Yes	Yes
Did the analysis include an intention to treat?	Yes	Yes	Yes	Yes	Yes	Yes